RESUMO
Objective: To estimate the costs of antimicrobials in patients with surgical site infections (SSI). Method: This is a descriptive, cross-sectional study with retrospective documentary analysis conducted at a tertiary public hospital with seven surgical rooms, averaging 750 surgeries per month.The micro-costing method used was the average direct cost of antibiotics, excluding intraoperative prophylactic antibiotics. Hospital infection investi-gation records were analyzed, and the study included records of patients diagnosed with confirmed surgical site infections (n=79) in 2021. Clinical data and direct costs of antimicrobials were examined. Results: The infection rate in this study was 6.76%. The specialties with the highest representation were digestive system and urological surgeries. Vancomycin was the most used antimicrobial, resulting in a total expenditure of R$ 7,345.68. Tigecycline incurred the highest total cost, amounting to R$ 79,655.52. Antimicrobials used to treat the 79 confirmed cases of SSIs totaled R$ 211,790.21 in costs. Conclusion: The average cost of antimicrobials per patient with SSI, considering total hospitalization days, was R$ 2,680.88, a significant component of total treatment costs. It is recommended to include cost analysis in the planning of hospital infection protocols. (AU)
Objetivo: Estimar los costos de los antimicrobianos en pacientes con infecciones del sitio quirúrgico (ISQ). Método: Este es un estudio descrip-tivo, transversal con análisis documental retrospectivo realizado en un hospital público terciario con siete salas quirúrgicas, con un promedio de 750 ciru-gías por mes. Se utilizó el método de microcosteo, calculando el costo directo promedio de los antibióticos, excluyendo los utilizados como profilaxis intraoperatoria. Se analizaron registros de investigación de infecciones hospitalarias, incluyendo pacientes diagnosticados con ISQ confirmadas (n=79) en 2021. Se examinaron datos clínicos y costos directos de los antimicrobianos. Resultados: La tasa de infección en este estudio fue del 6.76%. Las espe-cialidades con mayor representación fueron cirugías del sistema digestivo y urológicas. El antimicrobiano más utilizado fue la vancomicina, con un gasto total de R$ 7,345.68. Tigeciclina tuvo el costo total más alto, alcanzando R$ 79,655.52. Los antimicrobianos utilizados para tratar los 79 casos confirma-dos de ISQ sumaron R$ 211,790.21 en costos. Conclusión: El costo promedio de los antimicrobianos por paciente con ISQ, considerando los días totales de hospitalización, fue de R$ 2,680.88, un componente significativo de los costos totales de tratamiento. Se recomienda incluir análisis de costos en la planificación de protocolos de infección hospitalaria. (AU)
Objetivo: Estimar os custos com antimicrobianos em pacientes com infecções de sítio cirúrgico. Método: Trata-se de um estudo descritivo, trans-versal, com análise documental retrospectiva, realizado em um hospital público terciário, com sete salas cirúrgicas, onde se realizam em média 750 cirur-gias mensais. O método de microcusteio utilizado foi o custo direto médio dos antibióticos, não sendo incluído antibiótico profilático no intraoperatório. Analisaram-se as fichas de investigação de infecção hospitalar e foram incluídas no estudo as fichas de pacientes que tiveram o diagnóstico de infecção de sítio cirúrgico confirmado (n=79) em 2021. Foram verificados os dados clínicos e apenas os custos diretos com os antimicrobianos. Resultados: A taxa dessas infecções neste estudo foi de 6,76%. As especialidades com maior representatividade foram cirurgias do aparelho digestivo e urológicas. O antimi-crobiano mais utilizado foi a Vancomicina, resultando no gasto total de R$ 7.345,68. O medicamento que gerou maior custo total foi a Tigeciclina, que representou R$ 79.655,52. Os antimicrobianos utilizados para tratar dos 79 casos confirmados de ISCs totalizaram o custo de R$ 211.790,21. Conclusão: A média de custo com antimicrobiano por paciente com ISC, no total de dias internados, foi de R$ 2.680,88, valor considerado representativo no custo total do tratamento. Recomenda-se a inclusão de análise de custos no planejamento de protocolos de infecção hospitalar. (AU)
Assuntos
Humanos , Infecção da Ferida Cirúrgica , Custos de Cuidados de Saúde , Gestão de Antimicrobianos , Custos Hospitalares , Sistemas de Custos em Instituições de SaúdeRESUMO
OBJECTIVES: To analyse the use of polymyxins for the treatment of ventilator-associated pneumonia (VAP) at a teaching hospital where carbapenem-resistant gram-negative bacteria are endemic. PATIENTS AND METHODS: This was a historical cohort study of patients receiving polymyxins to treat VAP in ICUs at a public university hospital in southern Brazil between January 1, 2017 and January 31, 2018. RESULTS: During the study period, 179 cases of VAP were treated with polymyxins. Of the 179 patients, 158 (88.3%) were classified as having chronic critical illness. Death occurred in 145 cases (81.0%). Multivariate analysis showed that the factors independently associated with mortality were the presence of comorbidities (P<0.001) and the SOFA score of the day of polymyxin prescription (P<0.001). Being a burn patient was a protective factor for mortality (P<0.001). Analysis of the 14-day survival probability showed that mortality was higher among the patients who had sepsis or septic shock at the time of polymyxin prescription (P = 0.028 and P<0.001, respectively). Acinetobacter baumannii was identified as the etiological agent of VAP in 121 cases (67.6%). In our cohort, polymyxin consumption and the incidence density of VAP were quite high. CONCLUSIONS: In our study, comprised primarily of chronically critically ill patients, there was a high prevalence of VAP caused by multidrug-resistant bacteria, consistent with healthcare-associated infections in low- and middle-income countries. Presence of comorbidities and the SOFA score at the time of polymyxin prescription were predictors of mortality in this cohort. Despite aggressive antimicrobial treatment, mortality was high, stressing the need for antibiotic stewardship.
Assuntos
Carbapenêmicos/uso terapêutico , Farmacorresistência Bacteriana Múltipla , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/microbiologia , Polimixinas/uso terapêutico , Adulto , Idoso , Feminino , Mortalidade Hospitalar , Humanos , Incidência , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Pneumonia Associada à Ventilação Mecânica/mortalidade , Probabilidade , Análise de Sobrevida , Fatores de TempoRESUMO
BACKGROUND: Nitro-oxidative stress (NOS) has been implicated in the pathophysiology of psychiatric disorders. The activity of the polymorphic antioxidant enzyme paraoxonase 1 (PON1) is altered in diseases where NOS is involved. PON1 activity may be estimated using different substrates some of which are influenced by PON1 polymorphisms. OBJECTIVES: 1) to review the association between PON1 activities and psychiatric diseases using a standardized PON1 substrate terminology in order to offer a state-of-the-art review; and 2) to review the efficacy of different strategies (nutrition, drugs, lifestyle) to enhance PON1 activities. METHODS: The PubMed database was searched using the terms paraoxonase 1 and psychiatric diseases. Moreover, the database was also searched for clinical trials investigating strategies to enhance PON1 activity. RESULTS: The studies support decreased PON1 activity as determined using phenylacetate (i.e., arylesterase or AREase) as a substrate, in depression, bipolar disorder, generalized anxiety disorder (GAD) and schizophrenia, especially in antipsychotic-free patients. PON1 activity as determined with paraoxon (i.e., POase activity) yields more controversial results, which can be explained by the lack of adjustment for the Q192R polymorphism. The few clinical trials investigating the influence of nutritional, lifestyle and drugs on PON1 activities in the general population suggest that some polyphenols, oleic acid, Mediterranean diet, no smoking, being physically active and statins may be effective strategies that increase PON1 activity. CONCLUSION: Lowered PON1 activities appear to be a key component in the ongoing NOS processes that accompany affective disorders, GAD and schizophrenia. Treatments increasing attenuated PON1 activity could possibly be new drug targets for treating these disorders.
Assuntos
Arildialquilfosfatase/metabolismo , Transtornos Mentais/enzimologia , Estresse Nitrosativo/fisiologia , Estresse Oxidativo/fisiologia , Arildialquilfosfatase/análise , Humanos , Neurologistas , PsiquiatriaRESUMO
There is evidence that the acute phase of schizophrenia (SCZ) is accompanied by specific changes in oxidative and nitrosative stress (O&NS) biomarkers. There are, however, no firm data regarding these biomarkers in chronic SCZ. Therefore, this study aimed to delineate O&NS biomarkers in patients with chronic SCZ. 125 outpatients with SCZ and 118 controls were enrolled. The markers included lipid hydroperoxides (LOOH), advanced oxidation protein products (AOPP), nitric oxide metabolites (NOx), total radical-trapping antioxidant parameter (TRAP) and paraoxonase 1 (PON-1) activity. Immune-inflammatory markers known to be altered in SCZ were also measured: leptin, IL-6, soluble TNF receptors (sTNF-Rs) and the chemokines CCL-11 and CCL-3. There were no significant associations between chronic SCZ and the O&NS markers (AOPP, NOx, LOOH) and the anti-oxidants PON-1 and TRAP. Leptin, sTNF-R, CCL-3 and CCL-11 were significantly higher in SCZ. There were significant associations between pro-inflammatory and O&NS biomarkers (leptin/CCL-8 and AOPP; IL-6 and NOx; CCL-3 and LOOH; CCL-3/IL-6/NOx and TRAP). In conclusion, there were significant intercorrelations between inflammatory and O&NS pathways, which play a role in the pathophysiology of chronic SCZ. O&NS markers and the enzyme PON-1 are not useful as biomarkers in chronic stable polymedicated SCZ patients.
Assuntos
Estresse Nitrosativo/fisiologia , Estresse Oxidativo/fisiologia , Esquizofrenia/sangue , Adulto , Antioxidantes/análise , Biomarcadores/sangue , Estudos de Casos e Controles , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Óxido Nítrico/sangueRESUMO
Passiflora incarnata is marketed in many countries as a phytomedicine. Even though the directions of most marketed phytomedicines recommend them to be used under medical supervision, reproductive and developmental studies are sparse and not mandatory for regulatory purposes. In this study, a reproductive toxicity evaluation of P. incarnata was conducted in Wistar rats gavaged (30 or 300 mg/kg) during pregnancy and lactation. Moreover, considering that antioxidant properties have been attributed to flavonoids present in the genus Passiflora, it was also evaluated the antioxidant/pro-oxidant balance in the plasma of these dams and the antioxidant potential in an in vitro test. P. incarnata treatment did not influence dams´ body weight as well as reproductive (gestation length, post-implantation loss, litter size, litter weight) and hepatic (albumin, AST, ALT, GGT) parameters. The antioxidant property of P. incarnata was evidenced both in vivo (increase in the total antioxidant plasmatic potential) and in vitro (decrease in neutrophil-induced respiratory burst). The results from the present study indicate that under the experimental conditions evaluated, P. incarnata treatment during gestation and lactation presented antioxidant activity in the absence of maternal reproductive toxicity.
Passiflora incarnata é comercializada em muitos países como fitoterápico. Embora a bula da maioria dos fitoterápicos recomende que eles sejam usados sob supervisão médica, estudos sobre a toxicidade reprodutiva e do desenvolvimento desses produtos são raros e não obrigatórios para fins regulatórios. Neste estudo, realizamos uma avaliação da toxicidade reprodutiva da P. incarnata, administrada a ratas Wistar (30 ou 300 mg/kg, gavagem) durante a gestação e a lactação. Além disso, considerando as propriedades antioxidantes que têm sido atribuídas aos flavonoides presentes no gênero Passiflora, também avaliou-se o equilíbrio antioxidante/pró-oxidante no plasma destas fêmeas e conduziu-se um teste in vitro para avaliar o potencial antioxidante. O tratamento com P. incarnata não influenciou o peso corporal das fêmeas, bem como indicadores de toxicidade reprodutiva (perdas pós-implantação, número de filhotes vivos e peso da ninhada) e os parâmetros de função hepática (albumina, AST, ALT, GGT). A propriedade antioxidante da P. incarnata foi evidenciada tanto in vivo (aumento do potencial antioxidante total plasmático) quanto in vitro (diminuição do burst respiratório em neutrófilos). Os resultados deste estudo indicam que, nas condições experimentais avaliadas, o tratamento com P. incarnata durante a gestação e lactação apresentou efeito antioxidante, na ausência de toxicidade reprodutiva materna.